Superior prognostic value of three-dimensional echocardiography-derived right ventricular ejection fraction: a meta-analysis

ABSTRACT

Aims We aimed to confirm that three-dimensional echocardiography (3DE)-derived right ventricular (RV) ejection fraction (EF) is a more robust predictor of adverse cardiopulmonary outcomes than the conventional echocardiographic parameters.

Methods and Results We performed a meta-analysis of studies reporting the impact of unit change of RVEF, tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), and free-wall longitudinal strain (FWLS) on clinical outcomes (all-cause mortality and/or adverse cardiopulmonary outcomes). Hazard ratios (HR) were rescaled by the within-study standard deviations (SD) to represent standardized changes. Within each study, we calculated the ratio of HRs related to 1 SD reduction in RVEF versus TAPSE, or FAC, or FWLS, to quantify the predictive value of RVEF relative to the other metrics. These ratios of HRs were pooled using random-effects models.

Ten independent studies were identified as suitable, including data on 1,928 patients with various cardiopulmonary conditions. Overall, 1 SD reduction in RVEF was robustly associated with adverse outcomes (HR: 2.64 [95% CI: 2.18 to 3.20], p<0.001; heterogeneity: I²=65%, p=0.002). In studies reporting HRs for RVEF and TAPSE, FAC, or FWLS in the same cohort, RVEF had superior predictive value per SD reduction versus the other three parameters (vs. TAPSE, HR: 1.54 [95% CI: 1.04 to 2.28], p=0.031; vs. FAC, HR: 1.45 [95% CI: 1.15 to 1.81], p=0.001; vs. FWLS, HR: 1.44 [95% CI: 1.07 to 1.95], p=0.018).

Conclusion 3DE-derived RVEF has superior prognostic value compared with conventional RV indices, therefore, it might further refine the risk stratification of patients with cardiopulmonary diseases.

Graphical Abstract Added predictive value of three-dimensional (3D) echocardiography-derived right ventricular ejection fraction (RVEF) versus conventional metrics of RV systolic function on clinical outcomes: a meta-analysis of 10 studies. FAC: fractional area change, FWLS: free-wall longitudinal strain, HR: hazard ratio, SD: standard deviation, TAPSE: tricuspid annular plane systolic excursion

• Download figure
• Open in new tab

Competing Interest Statement

Drs. Tokodi, Fabian, Lakatos, and Kovacs report personal fees from Argus Cognitive, Inc., outside the submitted work. Dr. Friebel is a scientific advisor to Cardiovascular Imaging, Inc., Alberta, Canada, and receives personal fees for his services. Dr. Surkova received speaker fees from GE Healthcare and 123 sonography Ltd., outside the submitted work. Dr. Merkely reports grants from Boston Scientific and Medtronic, personal fees from Biotronic, Abbott, Astra Zeneca, Novartis, and Boehringer-Ingelheim, outside the submitted work. All other authors have no conflict of interest to declare.

Clinical Protocols

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018110771

Funding Statement

The research was supported by project NKFIH-1277-2/2020 by the Thematic Excellence Programme (2020-4.1.1.-TKP2020) of the Ministry for Innovation and Technology in Hungary, within the framework of the Bioimaging thematic programme of the Semmelweis University. Project no. RRF-2.3.1-21-2022-00003 has been implemented with the support provided by the European Union. The research was also supported by the UNKP-21-5 and the UNKP- 21-3-I New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund. Dr. Kovacs was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This meta-analysis used ONLY openly available human data that were originally located at PubMed or EMBASE. This meta-analysis was conducted according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Guidelines. The study protocol was preregistered on PROSPERO (registration number: CRD42018110771).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes